Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT219 alone and with cetuximab in advanced solid tumors and head and neck cancer
NCT04474470Phase 2Completed
- Sponsor
- TyrNovo Ltd.
- Start
- Sep 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of NT219 in solid tumor, squamous cell carcinoma of the head and neck (HNSCC), colorectal adenocarcinoma, sponsored by TyrNovo Ltd.. Started Sep 2020; status: completed.
02
Drugs
NT219
03
Conditions
solid tumorsquamous cell carcinoma of the head and neck (HNSCC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT04474470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04474470.